Hepatitis C virus NS5A protein increases hepatic lipid accumulation via induction of activation and expression of PPARgamma  by Kim, KyeongJin et al.
FEBS Letters 583 (2009) 2720–2726journal homepage: www.FEBSLetters .orgHepatitis C virus NS5A protein increases hepatic lipid accumulation via induction
of activation and expression of PPARgamma
KyeongJin Kim a, Kook Hwan Kim a, Eunsin Ha a, Jin Young Park a, Naoya Sakamoto b, JaeHun Cheong a,*
aDepartment of Molecular Biology, College of Natural Sciences, Pusan National University, Busan 609-735, Republic of Korea
bDepartment of Gastroenterology and Hepatology, Tokyo Medical and Dental University, Tokyo 113-8519, Japana r t i c l e i n f o
Article history:
Received 11 July 2009
Accepted 17 July 2009
Available online 23 July 2009
Edited by Hans-Dieter Klenk
Keywords:
Hepatitis C virus
NS5A
Lipid accumulation
PGC-1
PPARc0014-5793/$36.00  2009 Federation of European Bio
doi:10.1016/j.febslet.2009.07.034
* Corresponding author. Fax: +82 51 513 9258.
E-mail addresses: molecule85@pusan.ac.kr, jhcheoa b s t r a c t
Steatosis is an established risk factor for disease progression in cases of chronic hepatitis C. Recently
it was demonstrated that Hepatitis C virus (HCV) core and non-structural (NS) 2 proteins (NS2)
induce lipid accumulation in hepatic cells. However, it has yet to be determined whether other
HCV proteins are associated with lipid metabolism. The NS5A augmented the transcriptional activity
and gene expression of PPARc. Furthermore, NS5A increased the ability to recruit the transcriptional
coactivator PGC-1s to the PPRE with PPARc, as well as the interaction with PPARc2 and PGC-1a. Our
results indicate that NS5A may exploit multiple strategies that enhance PPARc-induced lipid accu-
mulation.
Structured summary:
MINT-7229685: PPAR gamma 2 (uniprotkb:P37231-2) physically interacts (MI:0914) with PGC1 alpha (uni-
protkb:Q9UBK2) by pull down (MI:0096)
MINT-7229712: PPAR gamma 2 (uniprotkb:P37231-2) physically interacts (MI:0914) with NS5A (uni-
protkb:P26662) by pull down (MI:0096)
MINT-7229698: PPAR gamma 2 (uniprotkb:P37231-2) physically interacts (MI:0914) with PGC1 alpha (uni-
protkb:Q9UBK2) by anti tag coimmunoprecipitation (MI:0007)
MINT-7229731: PPAR gamma 2 (uniprotkb:P37231-2) physically interacts (MI:0914) with NS5A (uni-
protkb:P26662) by anti tag coimmunoprecipitation (MI:0007)
 2009 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Hepatitis C virus (HCV) is classiﬁed into the genus Hepacivirus of
the family Flaviviridae [1]. As the case with all the members of this
family, HCV is an enveloped, single-stranded, and positive-sense
RNA virus. Upon translation, HCV polyprotein is proteolytically
processed by both cellular and viral proteases into at least 10 indi-
vidual proteins, including four structural proteins (core, E1, E2 and
p7) and six NS proteins (NS2, NS3, NS4A, NS4B, NS5A, and NS5B)
[2]. As the penultimate protein processed from HCV polyprotein
precursor, NS5A is a proline-rich hydrophilic phosphoprotein and
may exist in dimeric form [3]. Although no intrinsic enzymatic
activity has yet been ascribed to NS5A, it likely functions via inter-
actions with other NS proteins and host cell factors [2].
Peroxisome proliferators-activated receptors (PPARs) are li-
gand-activated nuclear receptors belonging to the steroid/thyroidchemical Societies. Published by E
ng2@lycos.co.kr (J. Cheong).hormone receptor superfamily; 3 isoforms designated as a, b/d,
and c exist, all of which are known to be involved in lipid homeo-
stasis. Increased PPARc expression has been reported in high-fat
diet-induced liver steatosis [4].
Chronic HCV infection may result in a wide clinical and prog-
nostic spectrum of severity and progression rates in cases of liver
disease, ranging from chronic hepatitis to cirrhosis and hepatocel-
lular carcinoma [5]. Hepatic steatosis is detected in almost 50% of
HCV-infected patients, which suggests that it is a crucial contribu-
tor to nonalcoholic fatty liver disease (NAFLD) [6], a severe and
progressive liver disease resulting in the development of cirrhosis
[7]. Recently, it has been reported that HCV core proteins increase
hepatic lipid accumulation via the activation of SREBP-1 and PPARc
[8], and that NS2 can upregulate the transcription of SREBP-1c and
fatty acid synthase (FAS) [9]. However, the precise molecular
mechanisms underlying HCV NS5A-associated steatosis have yet
to be clearly characterized. In this study, we explored the possibil-
ity that NS5A induces lipid accumulation in hepatocytes and the
activity and expression of PPARc may be deregulated, therefore
playing roles in NS5A-induced hepatic triglycerides deposits. Ourlsevier B.V. All rights reserved.
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involved in HCV-induced fatty liver disease.
2. Materials and methods
2.1. Plasmids, reagents, and antibodies
pNK/Flag/NS5A, pcDNA4/myc/PGC-1a, and pcDNA3/Flag/PGC-
1bwere generously donated by Dr. Seishi Murakami, Dr. Toren Fin-
kel, and Dr. Bruce M. Spiegelman [10–12]. pcDNA3/HA/PPARc,
pcDNA3/GFP/PPARc, pcDNA3/GST/PPARc, pcDNA3/HA/PGC-1a,
pM/PGC-1a, pVP16/PGC-1a, and pcDNA3/HA/NS5A constructs
were subcloned via the insertion of the PCR fragments of ORF into
pcDNA3/HA, pM (Gal4), pVP16 (Clontech), or pcDNA3/GFP [13,14].
Other constructs were all described previously [8,13].
Rosiglitazone and Ciglitazone were obtained from Cayman. The
transfection reagent PolyFect and JetPEI were purchased from QIA-
GEN and Polyplus-transfection. All other reagents were purchased
from Sigma. The antibodies against PPARc, GST, and GFP were pur-
chased from Santa Cruz Biotechnology Inc. and Actin, Flag, and HA-
antibody was obtained from Sigma, Cell Signaling, and Roche,
respectively. The anti-NS5A polyclonal antibody was kindly gifted
from Dr. Soon B. Hwang (Hallym University, Korea).
2.2. Cell culture and transient ransfection
Chang liver, HepG2, and Huh7 cell lines were maintained in
DMEM–10% fetal bovine serum (FBS; Abclone). Transient transfec-
tions were conducted using PolyFect or JetPEI with the indicated
reporter plasmids and mammalian expression vectors. Total
amounts of expression vectors were maintained at constant levels
via the addition of empty vectors. Relative luciferase activities
were measured with luciferin (BD Biosciences).Fig. 1. NS5A induces the transcriptional activity of PPARc in hepatocytes. (A) PPRE-tk-L
liver, HepG2, and Huh7 cells. Transfected cells were incubated in the presence or absence
luciferase reporter, PPARc2, and NS5A. Transfected cells were incubated for 24 h in the p
measured and values are expressed as means ± S.D. for at least two or more independen2.3. Establishment of Chang liver cells expressing NS5A proteins
Chang liver cells were transfected with 2 lg of pcDNA3/HA or
pcDNA3/HA/NS5A using JetPEI reagents in accordance with the
manufacturer’s instructions. After 48 h, the cells were grown in a
medium containing 800 lg/ml G418. Following 2 weeks of selec-
tion, sorted single cells were grown under an additional 2 weeks
of selection and expanded into stable cells. The candidate clones
were analyzed via Western blotting using speciﬁc HA-antibody.2.4. RNA isolation and RT-PCR
Total RNA was prepared using TRIzol (Invitrogen) in accordance
with the manufacturer’s recommendations. The cDNA was synthe-
sized from 3 lg of total RNA with Moloney murine leukemia virus
(MMLV) Reverse Transcriptase (Promega) using a random hexamer
(Cosmo, Korea) for 1 h at 37 C. A one-twenty ﬁfth aliquot of the
cDNAwas subjected to PCR ampliﬁcation using gene-speciﬁc prim-
ers. The PCR primers for PPARc gene ampliﬁcation were: 50-
GAAATGACCATGGTTGAC-30 (sense), 50-GATGCAGGCTCCACTTTG-30
(antisense); for NS5A ampliﬁcation: 50-TAGCAGTGCTCACTTCCAT-
GCTCA-30 (sense), 50-AGGATCTCCGCCGCAATGGATATT-30 (anti-
sense); for b-actin gene ampliﬁcation: 50-GACTACCTCATGAA-
GATC-30 (sense), and 50-GATCCACATCTGCTGGAA-30 (antisense).2.5. Establishment of Huh7 cells expressing HCV replicons and
interferon-cured cells
An HCV subgenomic replicon plasmid, pRep-Feo, was derived
from pRep-Neo (originally referred to as pHCVIbneo-delS) [15].
The pRep-Feo expressed a fusion gene comprised of ﬁreﬂy lucifer-
ase (Fluc) and neomycin phosphotransferase, as described else-uc was cotransfected with the expression vectors for PPARc1 and NS5A into Chang
of 10 lM Ciglitazone and Rosiglitazone. (B) Cells were cotransfected with a PPRE-tk-
resence or absence of 10 lM Ciglitazone and Rosiglitazone. Luciferase activity was
t experiments.
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merase and transfected into the Huh7 cells via electroporation.
After culturing in the presence of G418, the cell lines stably
expressing the replicons were established and designated Huh7/
Rep-Feo. To establish interferon-alpha (IFN-a)-cured cells, HCV
replicon cells were treated with 103 U/ml IFN-a (PBL Biomedical
Laboratories) for 10 days. The expression of HCV replicon was con-
ﬁrmed by RT-PCR and Western blotting.
2.6. In vivo interaction assays
Forty-eight hours after transfection, the cells were solubilized
with 300 ll of radioimmunoprecipitation assay (RIPA) buffer. The
cleared lysates were mixed with 40 ll of glutathione-sepharose
beads and rotated overnight at 4 C. The bound proteins were
eluted in 15 mM reduced glutathione, separated via SDS–PAGE,
and transferred to polyvinylidene diﬂuoride (PVDF) membranes
for blotting.Fig. 2. NS5A promotes PPARc mRNA and protein expression. (A) Chang liver, HepG2,
transactivate a PPARc2 promoter. (B) Cells were transfected with indicated expression pla
of PPARc gene expression in transiently NS5A-transfected Chang liver cells. RT-PCR andW
gene in Chang/HA/NS5A stable cells. Western blotting and RT-PCR were performed.
subgenomic replicon cells. RT-PCR and immunoblotting were performed as indicated.2.7. Coimmunoprecipitation
For the immunoprecipitations, cells were plated and transfected
as indicated plasmids. Cells were lysed via the addition of RIPA buf-
fer and an aliquot of the lysate was removed for the input control,
and the remainder was immunoprecipitated overnight with the
speciﬁc antibody and protein G-Sepharose (50% suspension; Invit-
rogen). The lysates and immunoprecipitates were separated via
SDS–PAGE and transferred onto PVDF membranes for blotting.
2.8. Oil Red O staining
ORO staining was conducted in accordance with the previously
described procedure, with minor modiﬁcations [14]. Cells were
stained overnight in freshly diluted ORO solution. The stain was
then removed, and the cells were washed twice with water and
absorbance of eluted ORO by adding 100% isopropanol at 500 nm
was measured in a spectrophotometer.and Huh7 cells expressing NS5A (50 and 100 ng) were assayed for their ability to
smid. After 48 h of transfection, luciferase activity was determined. (C) The increase
estern blotting were performed as indicated. (D) The enhanced expression of PPARc
(E) Total cell lysates or RNAs were harvested from Huh7, IFN-a-cured and HCV
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For the siRNA-mediated downregulation of PPARc, PPARc-spe-
ciﬁc siRNA and negative control siRNA were purchased from Bio-
neer (Daejeon, Korea). Chang liver cells were transfected with
either the siRNA molecule speciﬁc for PPARc or a negative control
siRNA using HiPerFect reagent (QIAGEN).
2.10. Statistical analysis
Statistical analyses were carried out by unpaired or paired t-test
as appropriate. All data are reported as means ± S.D. P value of
<0.05 was considered signiﬁcant.
3. Results
3.1. HCV NS5A induces the transcriptional activity of PPARc
Chronic hepatitis C (CHC) is associated frequently with hepatic
steatosis and PPARc cultivates hepatic steatosis. We investigated
the effect of nine individual proteins of HCV (core191, core-glyco-
protein E1 fusion protein, E2, and six NS proteins, NS2, NS3, NS4A,
NS4B, NS5A, and NS5B) on PPARc transactivation. In order to deter-Fig. 3. PGC-1s potentiate the PPARc-mediated transactivation with NS5A. (A and B) Chan
with PPARc1 (A) or PPARc2 (B) and NS5A in the presence or absence of PGC-1a and PGC
24 h. (C and D) Chang liver cells expressing PPARc1 (C), or PPARc2 (D), NS5A, PGC-1a, and
treated with 10 lM Rosiglitazone or vehicle for 24 h. Luciferase activity was measured.mine whether nine proteins affect the transcriptional activity of
PPARc, we cotransfected a reporter plasmid harboring multimer-
ized PPAR binding sites with the expression plasmid of PPARc1,
PPARc2, and nine proteins. In particular, core191 and NA5A signif-
icantly affected the transcriptional activity of PPARc1 and PPARc2.
Previously, we reported that core191 increases hepatic lipid accu-
mulation by SREBP1 and PPARc activation [8].
As shown in Fig. 1A and B, NS5A profoundly augmented the
activation of reporter gene expression by PPARc1 (Fig. 1A) and
PPARc2 (Fig. 1B) in the presence or absence of two synthetic PPARc
agonists, Ciglitazone and Rosiglitazone, in a variety of hepatic cell
lines. These results indicate that NS5A protein is an important reg-
ulator in HCV-induced PPARc activation.
3.2. HCV NS5A enhances the mRNA and protein expression of PPARc
It might be expected that the increased PPARc activity induced
by NS5A is accompanied by increases in the levels of its gene
expression. We found that NS5A augmented the promoter activity
of PPARc2 gene as a dose-dependent manner, as shown in compar-
isons of luciferase activity with basal levels (Fig. 2A). Since C/EBPa
has been reported to upregulate PPARc expression [16], we inves-
tigated the PPARc2-luciferase reporter activity with cotransfectiong liver cells were transiently transfected with PPRE-tk-Luc construct, in combination
-1b transfection. Cells were treated with 10 lM Rosiglitazone or vehicle (DMSO) for
PGC-1bwere assayed for their ability to transactivate the aP2 promoter. Cells were
2724 K. Kim et al. / FEBS Letters 583 (2009) 2720–2726of C/EBPa and NS5A expression plasmids. A reporter assay
indicated that NS5A increased the activity of PPARc2 promoter
in cooperation with C/EBPa as a dose-dependent manner
(Fig. 2B).
Furthermore, as shown in Fig. 2C, the mRNA and protein induc-
tion in RT-PCR and Western blotting were conﬁrmed for PPARc
expression by transiently transfected NS5A. In addition, to better
assess the role of NS5A protein in PPARc expression, we estab-
lished Chang liver cells evidencing stable expression of HA-tagged
NS5A proteins, and conﬁrmed the expression by immunoblotting
with the HA-antibody. We investigated that PPARc protein and
mRNA expression were signiﬁcantly elevated in Chang/HA/NS5A
stable cells (Fig. 2D).
To further investigate whether the expression of PPARc was
regulated by viral protein in the context of HCV RNA replication,
Huh7/Rep-Feo cells were treated with IFN-a for 10 days. The
mRNA and protein expression levels of PPARc were signiﬁcantly
elevated in HCV subgenomic replicon cells as compared with
Huh7 or the IFN-a-cured cells.Fig. 4. NS5A enhances the interaction with PPARc2 and PGC-1a. (A) Chang liver cells wer
and the reporter construct Gal4-tk-Luc. Cells were grown in the absence or presence o
various Gal4/DBD/PPARc fusion proteins. (B) Chang liver cells were cotransfected with
construct Gal4-tk-Luc. Cells were grown 24 h in the absence or presence of 10 lM Rosig
with expression vectors for Gal/PGC-1a, HA/NS5A, GST/PPARc2, and GST empty vector. W
glutathione-sepharose 4B bead and bounded proteins were analyzed by Western blot. (D
transfected cells were subjected to immunoprecipitation using antibodies speciﬁc for th
with antibodies speciﬁc for HA.3.3. HCV NS5A increases the transactivation of PGC-1s
PGC-1 was initially identiﬁed as a PPARc-interacting protein
from a BAT library, and was subsequently shown to associate with
an array of nuclear receptors (NRs) and transcription factors
[17,18]. Initially, the cotransfection of PGC-1a and PGC-1b with
PPARc1 (Fig. 3A) or PPARc2 (Fig. 3B) in the presence of NS5A
expression further stimulated transactivity of the PPRE promoter.
In particular, PGC-1a increased PPARc1 and PPARc2 activity more
in the presence of NS5A as compared to PGC-1b. We additionally
assessed the effects on the native promoter activity of adipocyte
fatty-acid-binding protein, aP2 (encoded by Ap2), a member of
the intracellular fatty-acid-binding protein (FABP) family, which
is an intact target of PPARc in adipose cells [19]. Although aP2
genes predominantly are not expressed in liver, we exploited the
overexpression of the aP2 promoter. As shown in Fig. 3C and D,
the cotransfection of PGC-1a and PGC-1b with PPARc1 (Fig. 3C)
or PPARc2 (Fig. 3D) and NS5A further elevated transcription from
the native promoters of aP2.e cotransfected with expression vectors encoding Gal4/PPARc2, VP16/PGC-1a, NS5A,
f 10 lM Rosiglitazone. The histogram represents the transcriptional activity of the
expression vectors encoding Gal4/PGC-1a, VP16/PPARc2, NS5A, and the reporter
litazone. The luciferase assay was performed. (C) Chang liver cells were transfected
hole cell lysates were incubated with GST or GST/PPARc2 fusion proteins bound to
) Chang liver cells were transfected with plasmids as indicated. Total lysates from
e GFP-epitope tag. Both lysates and precipitates were analyzed by immunoblotting
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Above results prompted us to attempt to investigate using var-
ious constructs whether the interaction between the PPARc and
PGC-1a enhances by NS5A proteins. We exploited the mammalian
two hybrid system. It was observed that the interaction between
Gal4-fused PPARc2 and VP16-fused PGC-1a was enhanced by
NS5A protein as a dose-dependent manner (Fig. 4A). Furthermore,
the reverse attempt using Gal4/PGC-1a and VP16/PPARc2 showed
effects similar to those observed in Fig. 5A (Fig. 4B).
In an effort to determine whether NS5A enhances the interac-
tion between PPARc2 and PGC-1a on the cellular level, we also em-
ployed other approaches. Chang liver cells were transfected with
constructs encoding for the GST-fused PPARc2, Gal-tagged PGC-
1a, and HA-tagged NS5A as indicated. As shown in Fig. 4C, the re-
sults of in vivo GST pulldown indicated that PGC-1a only inter-
acted with GST-PPARc2 and not GST proteins. Also, NS5A
signiﬁcantly enhanced the interaction between two proteins. We
observed similar results using coimmunoprecipitation using anti-
GFP antibodies. The GFP-tagged PPARc2 was bound to HA-tagged
PGC-1a and expression of NS5A enhanced the interaction of two
proteins (Fig. 4D). Collectively, these ﬁndings indicate that NS5A
performs a critical function in the formation of an active transcrip-
tional complex of PPARc2 and PGC-1a for PPARc activation.
3.5. PPARc is necessary for HCV NS5A-induced hepatic lipid
accumulation
In order to examine the effects of NS5A protein in the lipid accu-
mulation, Chang/HA/NS5A stable cells and parent Chang/HA stable
cells were stained with ORO. The percentage of ORO-positive cells
of Chang liver/HA/NS5A stable clone were signiﬁcantly higher than
in Chang/HA stable cells (Fig. 5A). Also, in an effort to determine
whether PPARc performs a function in NS5A-induced lipid accu-
mulation, we attempted to knockdown PPARc expression using
siRNA speciﬁc for PPARc. Chang liver cells were cotransfected with
the NS5A construct and/or siPPARc. As shown in Fig. 5B, siPPARc-
transfected cells did not affect hepatic lipid accumulation, even inFig. 5. HCV NS5A increases hepatic lipid accumulation. (A) The effect of expression of NS
Chang/HA/NS5A stable cells were analyzed by Western blotting using HA antibodies.
compared with parent stable cells. (B) The effect of PPARc in NS5A-induced lipid accumu
PPARc-speciﬁc siRNA was transfected with or without NS5A proteins into Chang liver
transfected with or without NS5A into Chang liver cells. Cells were stained with ORO anthe presence of NS5A. These results clearly indicate that PPARc is a
crucial transcription factor which mediates NS5A-induced lipid
accumulation.
4. Discussion
HCV infects >170 million individuals worldwide and causes li-
ver disease, including hepatic steatosis, cirrhosis, and eventually
hepatocellular carcinoma (HCC) [20]. The reported prevalence of
steatosis in patients with CHC varies between 40% and 80%,
depending on the features of the population studied with regard
to alcohol consumption, the prevalence of overweight/obesity, dia-
betes, and other risk factors of fatty liver [21]. HCV core protein
expression has been demonstrated to activate various pathways
of lipid metabolism [8,22,23]. However, the precise functions of
other proteins among HCV proteins in the development of fatty li-
ver remain to be determined.
NS5A interferes with the response to interferon and appears to
perform a crucial role in viral replication [24]. Also, NS5A aug-
ments the anti-apoptotic effect of bcl-2 and inhibits the pro-apop-
totic action of bax [25]. However, other functions of NS5A have yet
to be clearly deﬁned. In this report, our results provide the ﬁrst evi-
dence suggesting that NS5A protein can increase hepatic lipid
accumulation by inducing an increase in the expression and activ-
ity of PPARc.
It is well established that modulation of PPAR activity maintains
cellular and whole-body glucose and lipid homeostasis. Recent
studies have established a role for hepatic PPARc in the develop-
ment of hepatic steatosis in mouse model. According to these stud-
ies, hepatic PPARc is able to contribute to hepatic steatosis through
increasing hepatic triglyceride production and hepatic lipid uptake
[26,27].
In conclusion, we have determined that NS5A augments hepatic
PPARc activation and expression. It has been demonstrated that
NS5A enhances the recruitment of PGC-1a to PPARc via the
enhancement of interaction between these proteins. Hence, the re-
sults regarding NS5A pave the way for an important function as a
selective target of PPARc coactivation circuitry. Notably, we deter-5A proteins in hepatic lipid accumulation. The expression levels of NS5A protein in
ORO staining reveals the increased hepatic lipids in Chang/HA/NS5A stable cells
lation. For the siRNA-mediated downregulation of PPARc, negative control siRNA or
cells. The transfected cells were analyzed by Western blotting. The siPPARc were
d photographed. The absorbance of eluted ORO was determined at 500 nm.
2726 K. Kim et al. / FEBS Letters 583 (2009) 2720–2726mined that NS5A ameliorates hepatic lipid accumulation via the
regulation of PPARc and may contribute to HCV-induced hepatic
steatosis.
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